Arcus Biosciences (NYSE:RCUS) Stock Rating Lowered by Wall Street Zen

Arcus Biosciences (NYSE:RCUS) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other equities research analysts also recently weighed in on RCUS. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Citigroup reiterated a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Wedbush set a $35.00 target price on shares of Arcus Biosciences and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Morgan Stanley reiterated an “equal weight” rating and issued a $20.00 price target (down previously from $23.00) on shares of Arcus Biosciences in a research note on Thursday. Finally, Wells Fargo & Company boosted their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Monday, October 20th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and a consensus price target of $28.67.

Arcus Biosciences Price Performance

Arcus Biosciences stock opened at $21.02 on Friday. The firm has a market cap of $2.27 billion, a PE ratio of -6.11 and a beta of 0.77. Arcus Biosciences has a 52-week low of $6.50 and a 52-week high of $26.40. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The company’s 50 day moving average is $22.60 and its two-hundred day moving average is $15.64.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.06. The business had revenue of $26.00 million during the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company’s quarterly revenue was down 45.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.00) earnings per share. On average, research analysts expect that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

Insider Activity at Arcus Biosciences

In other news, COO Jennifer Jarrett sold 11,225 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total value of $245,603.00. Following the transaction, the chief operating officer owned 203,007 shares of the company’s stock, valued at approximately $4,441,793.16. The trade was a 5.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Juan C. Jaen sold 82,997 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $24.71, for a total value of $2,050,855.87. Following the sale, the president owned 954,063 shares of the company’s stock, valued at $23,574,896.73. This trade represents a 8.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 422,060 shares of company stock worth $9,286,202 in the last quarter. Company insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On Arcus Biosciences

Institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its position in shares of Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after acquiring an additional 1,021 shares during the period. SBI Securities Co. Ltd. raised its holdings in Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after purchasing an additional 2,845 shares during the last quarter. Abich Financial Wealth Management LLC purchased a new stake in Arcus Biosciences during the third quarter worth $69,000. CWM LLC boosted its position in Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after purchasing an additional 3,810 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after purchasing an additional 1,796 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.